Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton’s Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis
Xia Yao(Agro-Environmental Protection Institute), Yu Rao(Soochow University), Hongjiang Xu(National Center for Drug Screening), Shuyu Jin(Kyoto University), Ling Yang(Affiliated Hospital of Southwest Medical University), Xiuyun Sun(Tsinghua University)
Cited by 29
Related Papers
PROTACs: great opportunities for academia and industry
|Signal Transduction and Targeted Therapy|2019|627
PROTAC Technology: Opportunities and Challenges
|ACS Medicinal Chemistry Letters|2020|353
PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies
|Cell Research|2018|280
Chemistries of bifunctional PROTAC degraders
|Chemical Society Reviews|2022|270